Less than a week after completing the divestiture of several noncore assets, Evotec AG agreed to acquire Renovis Inc. in a $151.8 million stock deal. (BioWorld Today)

Less than a week after completing the divestiture of several noncore assets, Evotec AG agreed to acquire Renovis Inc. in a $151.8 million stock deal. (BioWorld Today)

Four months after licensing a preclinical, second-generation antisense drug for high cholesterol to Bristol-Myers Squibb Co. in a deal worth up to $192 million, Isis Pharmaceuticals Inc. is at it again. (BioWorld Today)

Four months after licensing a preclinical, second-generation antisense drug for high cholesterol to Bristol-Myers Squibb Co. in a deal worth up to $192 million, Isis Pharmaceuticals Inc. is at it again. (BioWorld Today)